|
|
|
|
|
|
Companies > Preclinical
|
|
|
Invenio has identified proprietary small molecules for the treatment of acute myeloid leukemia. The compounds function as differentiation inducing agents that attenuate the proliferative capacity of leukemic cells. Lead candidates are currently undergoing preclinical optimization.
Funders:
Grants
|
|
|
|
|